Laboratory tests for evaluating the individual's clotting mechanism.
The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
Use of a thrombelastograph, which provides a continuous graphic record of the physical shape of a clot during fibrin formation and subsequent lysis.
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS.
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
Clotting time of PLASMA mixed with a THROMBIN solution. It is a measure of the conversion of FIBRINOGEN to FIBRIN, which is prolonged by AFIBRINOGENEMIA, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, or HEPARIN. BATROXOBIN, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin.
Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.
Starches that have been chemically modified so that a percentage of OH groups are substituted with 2-hydroxyethyl ether groups.
A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.
Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.
An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.
An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.
A clinical condition resulting from repeated physical and psychological injuries inflicted on a child by the parents or caregivers.
The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.
The transfer of blood components such as erythrocytes, leukocytes, platelets, and plasma from a donor to a recipient or back to the donor. This process differs from the procedures undertaken in PLASMAPHERESIS and types of CYTAPHERESIS; (PLATELETPHERESIS and LEUKAPHERESIS) where, following the removal of plasma or the specific cell components, the remainder is transfused back to the donor.
The techniques used to draw blood from a vein for diagnostic purposes or for treatment of certain blood disorders such as erythrocytosis, hemochromatosis, polycythemia vera, and porphyria cutanea tarda.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
Agents that prevent clotting.
Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa.
Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).
Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.
A fibrin-stabilizing plasma enzyme (TRANSGLUTAMINASES) that is activated by THROMBIN and CALCIUM to form FACTOR XIIIA. It is important for stabilizing the formation of the fibrin polymer (clot) which culminates the coagulation cascade.
The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION.
The time required by whole blood to produce a visible clot.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Activated form of factor XI. In the intrinsic pathway, Factor XI is activated to XIa by factor XIIa in the presence of cofactor HMWK; (HIGH MOLECULAR WEIGHT KININOGEN). Factor XIa then activates factor IX to factor IXa in the presence of calcium.
Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
The natural enzymatic dissolution of FIBRIN.
The taking of a blood sample to determine its character as a whole, to identify levels of its component cells, chemicals, gases, or other constituents, to perform pathological examination, etc.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
Bleeding or escape of blood from a vessel.
Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.
Agents that cause clotting.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.
Activated form of factor IX. This activation can take place via the intrinsic pathway by the action of factor XIa and calcium, or via the extrinsic pathway by the action of factor VIIa, thromboplastin, and calcium. Factor IXa serves to activate factor X to Xa by cleaving the arginyl-leucine peptide bond in factor X.

Values of three coagulation screening tests of precolostral calves. (1/893)

Prothrombin times, partial thromboplastin times and platelet counts were performed to determine normal values and to screen for coagulation defects of precolostral calves. The precolostral calves were in two groups: one group of a few calves was tested two years before the second larger group. The results for both groups were similar. The tests were performed on postcolostral calves and on mature cows to compare their values with those of precolostral calves. The mean values of prothrombin times and partial thromboplastin times of precolostral calves in the first group were 18.8 seconds and 54.8 seconds respectively. The mean values of prothrombin times and partial thromboplastin times of precolostral calves in the second group were 18.8 seconds and 50.8 seconds respectively. The mean platelet count was 422,400/cmm for the first group and 482,800/cmm for the second group.  (+info)

Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis. (2/893)

Homozygous type I plasminogen deficiency has been identified as a cause of ligneous conjunctivitis. In this study, 5 additional patients with ligneous conjunctivitis are examined. Three unrelated patients (1 boy, 1 elderly woman, and 1 man) had plasminogen antigen levels of less than 0.4, less than 0.4, and 2.4 mg/dL, respectively, but had plasminogen functional residual activity of 17%, 18%, and 17%, respectively. These subjects were compound-heterozygotes for different missense mutations in the plasminogen gene: Lys19 --> Glu/Arg513 --> His, Lys19 --> Glu/Arg216 --> His, and Lys19 --> Glu/Leu128 --> Pro, respectively. The other 2 patients, a 14-year-old boy and his 19-year-old sister, who both presented with a severe course of the disease, exhibited plasminogen antigen and functional activity levels below the detection limit (<0.4 mg/dL and <5%, respectively). These subjects were compound-heterozygotes for a deletion mutation (del Lys212) and a splice site mutation in intron Q (Ex17 + 1del-g) in the plasminogen gene. These findings show that certain compound-heterozygous mutations in the plasminogen gene may be associated with ligneous conjunctivitis. Our findings also suggest that the severity of clinical symptoms of ligneous conjunctivitis and its associated complications may depend on the amount of plasminogen functional residual activity.  (+info)

Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. (3/893)

Polyethylene glycol (PEG)-hirudin is a derivative of hirudin with a long plasma half-life. We have compared the efficacy of PEG-hirudin with unfractionated heparin (UH) in preventing arterial thrombosis. Arterial thrombus formation was induced ex vivo in 12 healthy human volunteers by exposing a tissue factor-coated coverslip positioned in a parallel-plate perfusion chamber to flowing nonanticoagulated human blood drawn directly from an antecubital vein at an arterial wall shear rate of 2600 s-1 for 3.5 minutes. PEG-hirudin, UH, or saline (as control) were administered ex vivo through a heparin-coated mixing device positioned proximal to the perfusion chamber. Platelet and fibrin deposition was quantified by immunoenzymatic measure of the P-selectin and D-dimer content of dissolved plasmin-digested thrombi, respectively. UH was administered to a plasma concentration of 0.35 IU/mL. This concentration prolonged the activated partial thromboplastin time from 32+/-1 seconds to 79+/-4 seconds (P<0.01). UH did not significantly prevent platelet deposition. However, fibrin deposition was reduced by 39% (P<0.05). PEG-hirudin in plasma concentrations of 0.5, 2.5, and 5 microg/mL prolonged the activated partial thromboplastin time to 48+/-2, 87+/-4, and 118+/-4 seconds, respectively. In contrast to UH, PEG-hirudin prevented both platelet and fibrin deposition in a dose-dependent manner with a >80% reduction at 5 microg/mL (P<0.01). Furthermore, the plasma level of PEG-hirudin required to significantly prevent fibrin deposition (0.5 microg/mL) corresponded to a much shorter prolongation of activated partial thromboplastin time (48+/-2 seconds) than that needed for UH (79+/-4 seconds). Thus, our results are compatible with the view that thrombin is greatly involved in recruitment of platelets in evolving thrombi, and that PEG-hirudin is an effective agent for preventing arterial thrombosis in a human ex vivo experimental model.  (+info)

Abnormalities in liver function and coagulation profile following the Fontan procedure. (4/893)

OBJECTIVE: To investigate liver function and coagulation disorders in patients with a Fontan circulation at different time intervals after surgery. DESIGN: Retrospective analysis of clinical data and cross sectional study relating liver function and coagulation profile to time since surgery, in 28 surviving patients after the modified Fontan procedure. PATIENTS: 20 patients (71%) with atriopulmonary anastomosis, seven (25%) with atrioventricular anastomosis, and one (4%) with total cavopulmonary connection. Follow up ranged from 2.0 to 21.8 years (mean 11.1). RESULTS: Abnormal liver function tests, mainly reflecting cholestasis, were present in 21 patients who had a significantly longer follow up (p < 0.01). Protein synthesis was normal in almost all patients. Coagulation profile showed abnormalities in 22 patients. "Procoagulant" abnormalities-that is, decreased plasminogen and protein C activity-were found in 11 and five patients, respectively. The extent of these abnormalities was less in patients with a longer follow up. Anticoagulant abnormalities were factor V deficiency in 16 patients and factor VII deficiency in 17, resulting in a prolonged prothrombin time in 19 patients. Thirteen patients had both pro- and anticoagulant abnormalities. A prethrombotic state was present in five patients, with a significantly longer mean time interval since surgery (p = 0.05). Thus, although the individual procoagulant indices decreased with increasing time intervals since surgery, a prethrombotic state was found particularly in patients with a long term follow up. CONCLUSIONS: Mild cholestasis was mainly present in Fontan patients with a long duration of follow up. Along with laboratory procoagulant abnormalities indicating a prethrombotic state, anticoagulant abnormalities were also present. The coagulation profile varied at different time intervals after surgery. Thus detailed evaluation should be performed regularly, and the use of anticoagulants should be considered in every patient. Long term prospective studies are needed to evaluate the individual fluctuations of coagulation profile over time following a Fontan procedure.  (+info)

Comparative characterisation of Russell's viper (Daboia/Vipera russelli) venoms from different regions of the Indian peninsula. (5/893)

Russell's viper (Daboia/Vipera russelli) venom from different regions of India was subjected to chromatographic, electrophoretic, biochemical and immunological analysis. The elution profiles from ion-exchange chromatography and protein banding pattern from SDS-PAGE showed a significant variation in the constituents of venoms. The acidic proteins are found to be predominant in the venoms of eastern and western regions while basic proteins are the major contributors of the northern and southern regional venoms. The major variation of phospholipases A(2) in the venom samples of India may be described as: southern regional venom is rich in basic, toxic PLA(2) while this activity showed a dramatic decrease as one moves towards west, north and eastern regions of India. In addition, the caseinolytic, TAME-hydrolytic, anticoagulant, oedema-inducing and haemorrhagic activities of the venoms have also varied from one region to another. The muscle specimens of mice injected with venoms of different regions showed variable change in the muscle fibre damage and cell morphology. The eastern regional venom is most lethal among all the venoms. The lethal potencies for four regional venoms vary as: eastern>western>southern>northern. The polyclonal antibodies prepared against the venom of southern region showed cross-reaction with the venoms of other regions, but the extent of cross-reaction and diffusion patterns are different. However, the polyclonal antibodies prepared against southern regional venom showed no protection against lethal toxicity of other regional venoms.  (+info)

IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome. (6/893)

BACKGROUND AND OBJECTIVE: Autoantibodies to beta(2)-glycoprotein I (beta(2)-GPI) and/or prothrombin (FII) have been involved in the expression of lupus anticoagulant (LA) activity, an in vitro phenomenon associated with an increased risk of arterial and/or venous thromboembolic events. However, LA activity sustained by anti-FII antibodies has a much weaker association with thrombosis than LA activity sustained by anti-beta(2)-GPI antibodies. Because assays aimed at detecting LA activity are now commercially available, we evaluated the relative sensitivity to anti-FII and anti-beta(2)-GPI antibodies of a commercial LA assay in a consecutive series of patients with the clinical suspicion of anti-phospholipid antibody (APA) syndrome. DESIGN AND METHODS: One hundred and ten consecutive patients with the clinical suspicion of APA syndrome (primary in 39) and 36 healthy controls were evaluated for the presence of LA activity (LA, Staclot, Stago), anticardiolipin antibodies (Quanta Lite aCL IgG, IgM, Inova Diagnostics), and IgG binding to solid-phase and/or phospholipid (PL)-bound beta(2)-GPI and FII by ELISA assays developed an optimized in our laboratory. Odds ratios for the association of IgG binding activity with LA and the aCL IgG status were calculated. In LA patients, dependency of LA potency (as assessed by clotting time prolongation in absence or presence of hexagonal phospholipid) on autoantibody titers was analyzed by the generalized linear model. Total IgG fractions were purified from selected patients to evaluate their ability to inhibit prothrombin activation at low FII concentration. RESULTS: Anticardiolipin antibodies (aCL) of the IgG or IgM type were found in 64 and 23 patients and LA activity in 49 patients. Anti-beta(2)-GPI and anti-FII (solid-phase and PL-bound) IgG titers exceeding by more than 3 standard deviations the mean values observed in control subjects were found in 46 and 47 patients and in 56 and 30 patients respectively, with the highest titers detected in the subgroup of patients with both LA and aCL IgG. The relative risk of LA for patients free of anti-FII and/or anti-beta(2)-GPI IgG was 0.03 after stratification for the aCL IgG status. Anti-beta(2)-GPI (solid-phase and PL-bound) IgG (RR 34.4 and 12.6) and anti-FII (solid-phase) IgG (RR 6.33) were all associated with LA activity. However, when taking into account co-existence of anti-FII and anti-beta(2)-GPI IgG in the same patients, the relative risk of LA for patients with isolated anti-FII IgG (solid-phase and/or PL-bound) was 0.50, whereas it ranged from 4.24 to 8.70 for all the antibody combinations including anti-beta(2)-GPI IgG. Anti-beta(2)-GPI (PL-bound) and aCL IgG titers were the only significant predictors of LA potency determined in absence phospholipid (anti-beta(2)-GPI IgG) or in presence of hexagonal phospholipid (aCL IgG). Total IgG fractions purified from 12 patients (6 with anti-FII IgG) did not significantly inhibit factor II activity up to a 150-fold molar excess. INTERPRETATION AND CONCLUSIONS: These results highlight the high prevalence of anti-FII and anti-beta(2)-GPI IgG in patients with the clinical suspicion of APA syndrome and particularly in the subgroup of patients with LA activity. The fraction of LA activity which can be quenched by addition of hexagonal phospholipid is, however, only dependent on IgG directed to PL-bound beta(2)-GPI. Other antibodies associated with anticardiolipin IgG may explain residual clotting time prolongation observed in the presence of hexagonal phospholipid.  (+info)

Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults. (7/893)

BACKGROUND: Phylloquinone, found in dark-green vegetables and certain plant oils, is the primary dietary source of the fat-soluble vitamin K. Limited data suggest that the relative bioavailability of phylloquinone from vegetables is lower than that from a supplement. This finding is relevant to the maintenance of optimal vitamin K status. OBJECTIVE: The objective of this study was to compare, in younger and older adults, the relative bioavailability of phylloquinone from a vegetable with that of a fortified oil. DESIGN: In a crossover design with three 15-d residency periods in a metabolic unit, younger and older men and women (n = 36) consumed a mixed diet containing 100 microg phylloquinone/d. During 2 residency periods, the mixed diet was supplemented for 5 d with either broccoli (377 microg phylloquinone/d; broccoli diet) or phylloquinone-fortified oil (417 microg/d; oil diet). The relative bioavailability of phylloquinone was defined by the difference in plasma phylloquinone, percentage serum undercarboxylated osteocalcin (%ucOC), and urinary gamma-carboxyglutamic acid in response to 5 d of supplementation. RESULTS: For both younger and older adults, plasma phylloquinone concentrations were higher (P < 0.001) and %ucOC values were lower (P = 0.001) after the broccoli and oil diets than after the mixed diet only. Overall, the response to broccoli supplementation was not significantly different from the response to the fortified oil in either age group. Urinary gamma-carboxyglutamic acid did not change in response to supplementation. CONCLUSIONS: There was no significant difference in the relative bioavailability of phylloquinone, as evidenced by the lack of a significant difference in plasma phylloquinone and %ucOC between the 2 groups after either the broccoli or oil diets for younger and older adults.  (+info)

Laboratory evaluation of difenacoum as a rodenticide. (8/893)

The efficacy of difenacoum as a new anticoagulant rodenticide was evaluated by blood coagulation studies and laboratory feeding tests using warfarin-resistant and non-resistant common rats (Rattus norvegicus), ship rats (R. rattus) and house mice (Mus musculus). Prothrombin assays indicated that the compound had as marked an activity with warfarin-resistant common rats as coumatetralyl had with non-resistant animals. Feeding tests confirmed that 0-005% would be a near-optimal concentration for field use, although there was some evidence of unpalatability. Results with ship rats and house mice were less favourable. Trials with enclosed colonies of warfarin-resistant mice confirmed the laboratory finding that although difenacoum was more effective than all other currently used anticoagulants, it was unlikely to give complete control. It is concluded that difenacoum is a valuable new rodenticide, especiaaly for controlling warfarin-resistant common rats.  (+info)

Blood coagulation tests, also known as coagulation studies or clotting tests, are a series of medical tests used to evaluate the blood's ability to clot. These tests measure the functioning of various clotting factors and regulatory proteins involved in the coagulation cascade, which is a complex process that leads to the formation of a blood clot to prevent excessive bleeding.

The most commonly performed coagulation tests include:

1. Prothrombin Time (PT): Measures the time it takes for a sample of plasma to clot after the addition of calcium and tissue factor, which activates the extrinsic pathway of coagulation. The PT is reported in seconds and can be converted to an International Normalized Ratio (INR) to monitor anticoagulant therapy.
2. Activated Partial Thromboplastin Time (aPTT): Measures the time it takes for a sample of plasma to clot after the addition of calcium, phospholipid, and a contact activator, which activates the intrinsic pathway of coagulation. The aPTT is reported in seconds and is used to monitor heparin therapy.
3. Thrombin Time (TT): Measures the time it takes for a sample of plasma to clot after the addition of thrombin, which directly converts fibrinogen to fibrin. The TT is reported in seconds and can be used to detect the presence of fibrin degradation products or abnormalities in fibrinogen function.
4. Fibrinogen Level: Measures the amount of fibrinogen, a protein involved in clot formation, present in the blood. The level is reported in grams per liter (g/L) and can be used to assess bleeding risk or the effectiveness of fibrinogen replacement therapy.
5. D-dimer Level: Measures the amount of D-dimer, a protein fragment produced during the breakdown of a blood clot, present in the blood. The level is reported in micrograms per milliliter (µg/mL) and can be used to diagnose or exclude venous thromboembolism (VTE), such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

These tests are important for the diagnosis, management, and monitoring of various bleeding and clotting disorders. They can help identify the underlying cause of abnormal bleeding or clotting, guide appropriate treatment decisions, and monitor the effectiveness of therapy. It is essential to interpret these test results in conjunction with a patient's clinical presentation and medical history.

Blood coagulation, also known as blood clotting, is a complex process that occurs in the body to prevent excessive bleeding when a blood vessel is damaged. This process involves several different proteins and chemical reactions that ultimately lead to the formation of a clot.

The coagulation cascade is initiated when blood comes into contact with tissue factor, which is exposed after damage to the blood vessel wall. This triggers a series of enzymatic reactions that activate clotting factors, leading to the formation of a fibrin clot. Fibrin is a protein that forms a mesh-like structure that traps platelets and red blood cells to form a stable clot.

Once the bleeding has stopped, the coagulation process is regulated and inhibited to prevent excessive clotting. The fibrinolytic system degrades the clot over time, allowing for the restoration of normal blood flow.

Abnormalities in the blood coagulation process can lead to bleeding disorders or thrombotic disorders such as deep vein thrombosis and pulmonary embolism.

Partial Thromboplastin Time (PTT) is a medical laboratory test that measures the time it takes for blood to clot. It's more specifically a measure of the intrinsic and common pathways of the coagulation cascade, which are the series of chemical reactions that lead to the formation of a clot.

The test involves adding a partial thromboplastin reagent (an activator of the intrinsic pathway) and calcium to plasma, and then measuring the time it takes for a fibrin clot to form. This is compared to a control sample, and the ratio of the two times is calculated.

The PTT test is often used to help diagnose bleeding disorders or abnormal blood clotting, such as hemophilia or disseminated intravascular coagulation (DIC). It can also be used to monitor the effectiveness of anticoagulant therapy, such as heparin. Prolonged PTT results may indicate a bleeding disorder or an increased risk of bleeding, while shortened PTT results may indicate a hypercoagulable state and an increased risk of thrombosis.

Thromboelastography (TEG) is a viscoelastic method used to assess the kinetics of clot formation, clot strength, and fibrinolysis in whole blood. It provides a global assessment of hemostasis by measuring the mechanical properties of a clot as it forms and dissolves over time. The TEG graph displays several parameters that reflect the different stages of clotting, including reaction time (R), clot formation time (K), angle of clot formation (α), maximum amplitude (MA), and percentage lysis at 30 minutes (LY30). These parameters can help guide transfusion therapy and inform decisions regarding the management of coagulopathy in various clinical settings, such as trauma, cardiac surgery, liver transplantation, and obstetrics.

Blood coagulation disorders, also known as bleeding disorders or clotting disorders, refer to a group of medical conditions that affect the body's ability to form blood clots properly. Normally, when a blood vessel is injured, the body's coagulation system works to form a clot to stop the bleeding and promote healing.

In blood coagulation disorders, there can be either an increased tendency to bleed due to problems with the formation of clots (hemorrhagic disorder), or an increased tendency for clots to form inappropriately even without injury, leading to blockages in the blood vessels (thrombotic disorder).

Examples of hemorrhagic disorders include:

1. Hemophilia - a genetic disorder that affects the ability to form clots due to deficiencies in clotting factors VIII or IX.
2. Von Willebrand disease - another genetic disorder caused by a deficiency or abnormality of the von Willebrand factor, which helps platelets stick together to form a clot.
3. Liver diseases - can lead to decreased production of coagulation factors, increasing the risk of bleeding.
4. Disseminated intravascular coagulation (DIC) - a serious condition where clotting and bleeding occur simultaneously due to widespread activation of the coagulation system.

Examples of thrombotic disorders include:

1. Factor V Leiden mutation - a genetic disorder that increases the risk of inappropriate blood clot formation.
2. Antithrombin III deficiency - a genetic disorder that impairs the body's ability to break down clots, increasing the risk of thrombosis.
3. Protein C or S deficiencies - genetic disorders that lead to an increased risk of thrombosis due to impaired regulation of the coagulation system.
4. Antiphospholipid syndrome (APS) - an autoimmune disorder where the body produces antibodies against its own clotting factors, increasing the risk of thrombosis.

Treatment for blood coagulation disorders depends on the specific diagnosis and may include medications to manage bleeding or prevent clots, as well as lifestyle changes and monitoring to reduce the risk of complications.

Prothrombin time (PT) is a medical laboratory test that measures the time it takes for blood to clot. It's often used to evaluate the functioning of the extrinsic and common pathways of the coagulation system, which is responsible for blood clotting. Specifically, PT measures how long it takes for prothrombin (a protein produced by the liver) to be converted into thrombin, an enzyme that converts fibrinogen into fibrin and helps form a clot.

Prolonged PT may indicate a bleeding disorder or a deficiency in coagulation factors, such as vitamin K deficiency or the use of anticoagulant medications like warfarin. It's important to note that PT is often reported with an international normalized ratio (INR), which allows for standardization and comparison of results across different laboratories and reagent types.

Blood coagulation factors, also known as clotting factors, are a group of proteins that play a crucial role in the blood coagulation process. They are essential for maintaining hemostasis, which is the body's ability to stop bleeding after injury.

There are 13 known blood coagulation factors, and they are designated by Roman numerals I through XIII. These factors are produced in the liver and are normally present in an inactive form in the blood. When there is an injury to a blood vessel, the coagulation process is initiated, leading to the activation of these factors in a specific order.

The coagulation cascade involves two pathways: the intrinsic and extrinsic pathways. The intrinsic pathway is activated when there is damage to the blood vessel itself, while the extrinsic pathway is activated by tissue factor released from damaged tissues. Both pathways converge at the common pathway, leading to the formation of a fibrin clot.

Blood coagulation factors work together in a complex series of reactions that involve activation, binding, and proteolysis. When one factor is activated, it activates the next factor in the cascade, and so on. This process continues until a stable fibrin clot is formed.

Deficiencies or abnormalities in blood coagulation factors can lead to bleeding disorders such as hemophilia or thrombosis. Hemophilia is a genetic disorder that affects one or more of the coagulation factors, leading to excessive bleeding and difficulty forming clots. Thrombosis, on the other hand, occurs when there is an abnormal formation of blood clots in the blood vessels, which can lead to serious complications such as stroke or pulmonary embolism.

Disseminated Intravascular Coagulation (DIC) is a complex medical condition characterized by the abnormal activation of the coagulation cascade, leading to the formation of blood clots in small blood vessels throughout the body. This process can result in the consumption of clotting factors and platelets, which can then lead to bleeding complications. DIC can be caused by a variety of underlying conditions, including sepsis, trauma, cancer, and obstetric emergencies.

The term "disseminated" refers to the widespread nature of the clotting activation, while "intravascular" indicates that the clotting is occurring within the blood vessels. The condition can manifest as both bleeding and clotting complications, which can make it challenging to diagnose and manage.

The diagnosis of DIC typically involves laboratory tests that evaluate coagulation factors, platelet count, fibrin degradation products, and other markers of coagulation activation. Treatment is focused on addressing the underlying cause of the condition while also managing any bleeding or clotting complications that may arise.

Thrombin time (TT) is a medical laboratory test that measures the time it takes for a clot to form after thrombin, an enzyme that converts fibrinogen to fibrin in the final step of the coagulation cascade, is added to a plasma sample. This test is used to evaluate the efficiency of the conversion of fibrinogen to fibrin and can be used to detect the presence of abnormalities in the coagulation system, such as the presence of heparin or dysfibrinogenemia. Increased thrombin time may indicate the presence of a systemic anticoagulant or a deficiency in fibrinogen.

Fibrinogen is a soluble protein present in plasma, synthesized by the liver. It plays an essential role in blood coagulation. When an injury occurs, fibrinogen gets converted into insoluble fibrin by the action of thrombin, forming a fibrin clot that helps to stop bleeding from the injured site. Therefore, fibrinogen is crucial for hemostasis, which is the process of stopping bleeding and starting the healing process after an injury.

Hydroxyethyl starch derivatives are modified starches that are used as plasma expanders in medicine. They are created by chemically treating corn, potato, or wheat starch with hydroxylethyl groups, which makes the starch more soluble and less likely to be broken down by enzymes in the body. This results in a large molecule that can remain in the bloodstream for an extended period, increasing intravascular volume and improving circulation.

These derivatives are available in different molecular weights and substitution patterns, which affect their pharmacokinetics and pharmacodynamics. They are used to treat or prevent hypovolemia (low blood volume) due to various causes such as bleeding, burns, or dehydration. Common brand names include Hetastarch, Pentastarch, and Voluven.

It's important to note that the use of hydroxyethyl starch derivatives has been associated with adverse effects, including kidney injury, coagulopathy, and pruritus (severe itching). Therefore, their use should be carefully monitored and restricted to specific clinical situations.

Prothrombin is a protein present in blood plasma, and it's also known as coagulation factor II. It plays a crucial role in the coagulation cascade, which is a complex series of reactions that leads to the formation of a blood clot.

When an injury occurs, the coagulation cascade is initiated to prevent excessive blood loss. Prothrombin is converted into its active form, thrombin, by another factor called factor Xa in the presence of calcium ions, phospholipids, and factor Va. Thrombin then catalyzes the conversion of fibrinogen into fibrin, forming a stable clot.

Prothrombin levels can be measured through a blood test, which is often used to diagnose or monitor conditions related to bleeding or coagulation disorders, such as liver disease or vitamin K deficiency.

Thromboplastin is a substance that activates the coagulation cascade, leading to the formation of a clot (thrombus). It's primarily found in damaged or injured tissues and blood vessels, as well as in platelets (thrombocytes). There are two types of thromboplastin:

1. Extrinsic thromboplastin (also known as tissue factor): This is a transmembrane glycoprotein that is primarily found in subendothelial cells and released upon injury to the blood vessels. It initiates the extrinsic pathway of coagulation by binding to and activating Factor VII, ultimately leading to the formation of thrombin and fibrin clots.
2. Intrinsic thromboplastin (also known as plasma thromboplastin or factor III): This term is used less frequently and refers to a labile phospholipid component present in platelet membranes, which plays a role in the intrinsic pathway of coagulation.

In clinical settings, the term "thromboplastin" often refers to reagents used in laboratory tests like the prothrombin time (PT) and activated partial thromboplastin time (aPTT). These reagents contain a source of tissue factor and calcium ions to initiate and monitor the coagulation process.

Hemostatics are substances or agents that promote bleeding cessation or prevent the spread of bleeding. They can act in various ways, such as by stimulating the body's natural clotting mechanisms, constricting blood vessels to reduce blood flow, or forming a physical barrier to block the bleeding site.

Hemostatics are often used in medical settings to manage wounds, injuries, and surgical procedures. They can be applied directly to the wound as a powder, paste, or gauze, or they can be administered systemically through intravenous injection. Examples of hemostatic agents include fibrin sealants, collagen-based products, thrombin, and oxidized regenerated cellulose.

It's important to note that while hemostatics can be effective in controlling bleeding, they should be used with caution and only under the guidance of a healthcare professional. Inappropriate use or overuse of hemostatic agents can lead to complications such as excessive clotting, thrombosis, or tissue damage.

I'm sorry for any confusion, but "Lupus Coagulation Inhibitor" is not a recognized medical term or concept in hematology or immunology.

Systemic Lupus Erythematosus (SLE), often referred to simply as lupus, is an autoimmune disease where the body's immune system mistakenly attacks healthy tissue. However, this does not result in a specific coagulation inhibitor.

If you're asking about lupus anticoagulants, these are antibodies that can interfere with clotting tests but paradoxically increase the risk of blood clots in vivo. They are sometimes seen in patients with SLE and other autoimmune diseases.

Please provide more context if you meant something else, so I can give a more accurate response.

Thrombin is a serine protease enzyme that plays a crucial role in the coagulation cascade, which is a complex series of biochemical reactions that leads to the formation of a blood clot (thrombus) to prevent excessive bleeding during an injury. Thrombin is formed from its precursor protein, prothrombin, through a process called activation, which involves cleavage by another enzyme called factor Xa.

Once activated, thrombin converts fibrinogen, a soluble plasma protein, into fibrin, an insoluble protein that forms the structural framework of a blood clot. Thrombin also activates other components of the coagulation cascade, such as factor XIII, which crosslinks and stabilizes the fibrin network, and platelets, which contribute to the formation and growth of the clot.

Thrombin has several regulatory mechanisms that control its activity, including feedback inhibition by antithrombin III, a plasma protein that inactivates thrombin and other serine proteases, and tissue factor pathway inhibitor (TFPI), which inhibits the activation of factor Xa, thereby preventing further thrombin formation.

Overall, thrombin is an essential enzyme in hemostasis, the process that maintains the balance between bleeding and clotting in the body. However, excessive or uncontrolled thrombin activity can lead to pathological conditions such as thrombosis, atherosclerosis, and disseminated intravascular coagulation (DIC).

Battered Child Syndrome is a medical condition in which a child has been physically abused and harmed, often over a period of time. It is also known as Non-accidental Injury (NAI) or Inflicted Traumatic Injury. The syndrome is characterized by a pattern of injuries, including bruises, fractures, burns, and internal injuries, which are not consistent with the history provided by the caregiver.

The symptoms of Battered Child Syndrome may include:

1. Unexplained or inconsistent explanations for injuries
2. Multiple injuries in various stages of healing
3. Injuries to different parts of the body, such as the ears, mouth, and genitals
4. Frequent visits to the emergency department or doctor's office for treatment of injuries
5. Delayed seeking of medical attention for serious injuries
6. Behavioral changes, such as fearfulness, regression, or aggression
7. Developmental delays or learning difficulties
8. Failure to thrive (poor growth and weight gain)

The diagnosis of Battered Child Syndrome is made by a healthcare professional based on the history, physical examination, and any diagnostic tests that may be necessary. The syndrome is a serious form of child abuse that requires immediate intervention and protection for the child. Treatment typically involves medical care for injuries, counseling and support for the child and family, and reporting the abuse to child protective services or law enforcement agencies.

Hemostasis is the physiological process that occurs to stop bleeding (bleeding control) when a blood vessel is damaged. This involves the interaction of platelets, vasoconstriction, and blood clotting factors leading to the formation of a clot. The ultimate goal of hemostasis is to maintain the integrity of the vascular system while preventing excessive blood loss.

A blood component transfusion is the process of transferring a specific component of donated blood into a recipient's bloodstream. Blood components include red blood cells, plasma, platelets, and cryoprecipitate (a fraction of plasma that contains clotting factors). These components can be separated from whole blood and stored separately to allow for targeted transfusions based on the individual needs of the patient.

For example, a patient who is anemic may only require a red blood cell transfusion, while a patient with severe bleeding may need both red blood cells and plasma to replace lost volume and clotting factors. Platelet transfusions are often used for patients with low platelet counts or platelet dysfunction, and cryoprecipitate is used for patients with factor VIII or fibrinogen deficiencies.

Blood component transfusions must be performed under strict medical supervision to ensure compatibility between the donor and recipient blood types and to monitor for any adverse reactions. Proper handling, storage, and administration of blood components are also critical to ensure their safety and efficacy.

Phlebotomy is a medical term that refers to the process of making an incision in a vein, usually in the arm, in order to draw blood. It is also commonly known as venipuncture. This procedure is performed by healthcare professionals for various purposes such as diagnostic testing, blood donation, or therapeutic treatments like phlebotomy for patients with hemochromatosis (a condition where the body absorbs too much iron from food).

The person who performs this procedure is called a phlebotomist. They must be trained in the proper techniques to ensure that the process is safe and relatively pain-free for the patient, and that the blood sample is suitable for laboratory testing.

Factor Xa is a serine protease that plays a crucial role in the coagulation cascade, which is a series of reactions that lead to the formation of a blood clot. It is one of the activated forms of Factor X, a pro-protein that is converted to Factor Xa through the action of other enzymes in the coagulation cascade.

Factor Xa functions as a key component of the prothrombinase complex, which also includes calcium ions, phospholipids, and activated Factor V (also known as Activated Protein C or APC). This complex is responsible for converting prothrombin to thrombin, which then converts fibrinogen to fibrin, forming a stable clot.

Inhibitors of Factor Xa are used as anticoagulants in the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism. These drugs work by selectively inhibiting Factor Xa, thereby preventing the formation of the prothrombinase complex and reducing the risk of clot formation.

Anticoagulants are a class of medications that work to prevent the formation of blood clots in the body. They do this by inhibiting the coagulation cascade, which is a series of chemical reactions that lead to the formation of a clot. Anticoagulants can be given orally, intravenously, or subcutaneously, depending on the specific drug and the individual patient's needs.

There are several different types of anticoagulants, including:

1. Heparin: This is a naturally occurring anticoagulant that is often used in hospitalized patients who require immediate anticoagulation. It works by activating an enzyme called antithrombin III, which inhibits the formation of clots.
2. Low molecular weight heparin (LMWH): LMWH is a form of heparin that has been broken down into smaller molecules. It has a longer half-life than standard heparin and can be given once or twice daily by subcutaneous injection.
3. Direct oral anticoagulants (DOACs): These are newer oral anticoagulants that work by directly inhibiting specific clotting factors in the coagulation cascade. Examples include apixaban, rivaroxaban, and dabigatran.
4. Vitamin K antagonists: These are older oral anticoagulants that work by inhibiting the action of vitamin K, which is necessary for the formation of clotting factors. Warfarin is an example of a vitamin K antagonist.

Anticoagulants are used to prevent and treat a variety of conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and prosthetic heart valve thrombosis. It is important to note that anticoagulants can increase the risk of bleeding, so they must be used with caution and regular monitoring of blood clotting times may be required.

Factor VII, also known as proconvertin, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor VII is synthesized in the liver and is activated when it comes into contact with tissue factor, which is exposed when blood vessels are damaged. Activated Factor VII then activates Factor X, leading to the formation of thrombin and ultimately a fibrin clot.

Inherited deficiencies or dysfunctions of Factor VII can lead to an increased risk of bleeding, while elevated levels of Factor VII have been associated with an increased risk of thrombosis (blood clots).

Factor X is a protein that is essential for blood clotting, also known as coagulation. It is an enzyme that plays a crucial role in the coagulation cascade, which is a series of chemical reactions that lead to the formation of a blood clot. Factor X is activated by one of two pathways: the intrinsic pathway, which is initiated by damage to the blood vessels, or the extrinsic pathway, which is triggered by the release of tissue factor from damaged cells. Once activated, Factor X converts prothrombin to thrombin, which then converts fibrinogen to fibrin to form a stable clot.

Inherited deficiencies in Factor X can lead to bleeding disorders, while increased levels of Factor X have been associated with an increased risk of thrombosis or blood clots. Therefore, maintaining appropriate levels of Factor X is important for the proper balance between bleeding and clotting in the body.

A platelet count is a laboratory test that measures the number of platelets, also known as thrombocytes, in a sample of blood. Platelets are small, colorless cell fragments that circulate in the blood and play a crucial role in blood clotting. They help to stop bleeding by sticking together to form a plug at the site of an injured blood vessel.

A normal platelet count ranges from 150,000 to 450,000 platelets per microliter (µL) of blood. A lower than normal platelet count is called thrombocytopenia, while a higher than normal platelet count is known as thrombocytosis.

Abnormal platelet counts can be a sign of various medical conditions, including bleeding disorders, infections, certain medications, and some types of cancer. It is important to consult with a healthcare provider if you have any concerns about your platelet count or if you experience symptoms such as easy bruising, prolonged bleeding, or excessive menstrual flow.

Factor IX is also known as Christmas factor, which is a protein that plays a crucial role in the coagulation cascade, a series of chemical reactions that leads to the formation of a blood clot. It is one of the essential components required for the proper functioning of the body's natural blood-clotting mechanism.

Factor IX is synthesized in the liver and activated when it comes into contact with an injured blood vessel. Once activated, it collaborates with other factors to convert factor X to its active form, which then converts prothrombin to thrombin. Thrombin is responsible for converting fibrinogen to fibrin, forming a stable fibrin clot that helps stop bleeding and promote healing.

Deficiencies in Factor IX can lead to hemophilia B, a genetic disorder characterized by prolonged bleeding and an increased risk of spontaneous bleeding. Hemophilia B is inherited in an X-linked recessive pattern, meaning it primarily affects males, while females serve as carriers of the disease. Treatment for hemophilia B typically involves replacing the missing or deficient Factor IX through infusions to prevent or manage bleeding episodes.

Factor VIIa is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor VIIa is the activated form of factor VII, which is normally activated by tissue factor (TF) when there is damage to the blood vessels. Together, TF and Factor VIIa convert Factor X to its active form, Factor Xa, which then converts prothrombin to thrombin, leading to the formation of a fibrin clot.

In summary, Factor VIIa is an important protein in the coagulation cascade that helps to initiate the formation of a blood clot in response to injury.

Factor XIII, also known as fibrin stabilizing factor, is a protein involved in the clotting process of blood. It is a transglutaminase enzyme that cross-links fibrin molecules to form a stable clot. Factor XIII becomes activated during the coagulation cascade, and its activity helps strengthen the clot and protect it from premature degradation by proteolytic enzymes. A deficiency in Factor XIII can lead to a bleeding disorder characterized by prolonged bleeding after injury or surgery.

In the context of medicine, plasma refers to the clear, yellowish fluid that is the liquid component of blood. It's composed of water, enzymes, hormones, antibodies, clotting factors, and other proteins. Plasma serves as a transport medium for cells, nutrients, waste products, gases, and other substances throughout the body. Additionally, it plays a crucial role in the immune response and helps regulate various bodily functions.

Plasma can be collected from blood donors and processed into various therapeutic products, such as clotting factors for people with hemophilia or immunoglobulins for patients with immune deficiencies. This process is called plasma fractionation.

Whole Blood Coagulation Time (WBCT) is not a standard term used in medical literature. However, I believe you may be referring to "bleeding time" or "coagulation time" which are tests used to evaluate the function of the blood's clotting system.

Bleeding time is a measure of how long it takes for bleeding to stop after a small cut is made in the skin. It helps assess the function of the platelets and the smaller blood vessels.

Coagulation time, on the other hand, measures the time it takes for a larger clot to form in whole blood. This test is not commonly used in clinical practice.

It's important to note that these tests have largely been replaced by more specific coagulation tests, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), which provide more detailed information about the different components of the clotting system.

Heparin is defined as a highly sulfated glycosaminoglycan (a type of polysaccharide) that is widely present in many tissues, but is most commonly derived from the mucosal tissues of mammalian lungs or intestinal mucosa. It is an anticoagulant that acts as an inhibitor of several enzymes involved in the blood coagulation cascade, primarily by activating antithrombin III which then neutralizes thrombin and other clotting factors.

Heparin is used medically to prevent and treat thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and certain types of heart attacks. It can also be used during hemodialysis, cardiac bypass surgery, and other medical procedures to prevent the formation of blood clots.

It's important to note that while heparin is a powerful anticoagulant, it does not have any fibrinolytic activity, meaning it cannot dissolve existing blood clots. Instead, it prevents new clots from forming and stops existing clots from growing larger.

Factor XIa is a serine protease enzyme that plays a crucial role in blood coagulation. It is formed through the activation of Factor XI, which is one of the key components in the intrinsic pathway of the coagulation cascade. The activation of Factor XI to Factor XIa occurs via either autoactivation or through the action of thrombin. Once activated, Factor XIa can cleave and activate Factor IX, leading to the formation of Factor IXa, which further amplifies the coagulation cascade.

In summary, Factor XIa is a vital enzyme in the blood coagulation process, contributing to the formation of a stable fibrin clot that helps prevent excessive bleeding during injury or trauma.

Factor VIII is a protein in the blood that is essential for normal blood clotting. It is also known as antihemophilic factor (AHF). Deficiency or dysfunction of this protein results in hemophilia A, a genetic disorder characterized by prolonged bleeding and easy bruising. Factor VIII works together with other proteins to help form a clot and stop bleeding at the site of an injury. It acts as a cofactor for another clotting factor, IX, in the so-called intrinsic pathway of blood coagulation. Intravenous infusions of Factor VIII concentrate are used to treat and prevent bleeding episodes in people with hemophilia A.

Fibrinolysis is the natural process in the body that leads to the dissolution of blood clots. It is a vital part of hemostasis, the process that regulates bleeding and wound healing. Fibrinolysis occurs when plasminogen activators convert plasminogen to plasmin, an enzyme that breaks down fibrin, the insoluble protein mesh that forms the structure of a blood clot. This process helps to prevent excessive clotting and maintains the fluidity of the blood. In medical settings, fibrinolysis can also refer to the therapeutic use of drugs that stimulate this process to dissolve unwanted or harmful blood clots, such as those that cause deep vein thrombosis or pulmonary embolism.

Blood specimen collection is the process of obtaining a sample of blood from a patient for laboratory testing and analysis. This procedure is performed by trained healthcare professionals, such as nurses or phlebotomists, using sterile equipment to minimize the risk of infection and ensure accurate test results. The collected blood sample may be used to diagnose and monitor various medical conditions, assess overall health and organ function, and check for the presence of drugs, alcohol, or other substances. Proper handling, storage, and transportation of the specimen are crucial to maintain its integrity and prevent contamination.

A "Blood Cell Count" is a medical laboratory test that measures the number of red blood cells (RBCs), white blood cells (WBCs), and platelets in a sample of blood. This test is often used as a part of a routine check-up or to help diagnose various medical conditions, such as anemia, infection, inflammation, and many others.

The RBC count measures the number of oxygen-carrying cells in the blood, while the WBC count measures the number of immune cells that help fight infections. The platelet count measures the number of cells involved in clotting. Abnormal results in any of these counts may indicate an underlying medical condition and further testing may be required for diagnosis and treatment.

Hemorrhage is defined in the medical context as an excessive loss of blood from the circulatory system, which can occur due to various reasons such as injury, surgery, or underlying health conditions that affect blood clotting or the integrity of blood vessels. The bleeding may be internal, external, visible, or concealed, and it can vary in severity from minor to life-threatening, depending on the location and extent of the bleeding. Hemorrhage is a serious medical emergency that requires immediate attention and treatment to prevent further blood loss, organ damage, and potential death.

Blood coagulation factor inhibitors are substances that interfere with the normal blood clotting process by inhibiting the function of coagulation factors. These inhibitors can be either naturally occurring or artificially produced.

Naturally occurring coagulation factor inhibitors include antithrombin, protein C, and tissue factor pathway inhibitor (TFPI). These inhibitors play a crucial role in regulating the coagulation cascade and preventing excessive clot formation.

Artificially produced coagulation factor inhibitors are used as therapeutic agents to treat thrombotic disorders. Examples include direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran, which selectively inhibit specific coagulation factors (factor Xa or thrombin).

Additionally, there are also antibodies that can act as coagulation factor inhibitors. These include autoantibodies that develop in some individuals and cause bleeding disorders such as acquired hemophilia A or antiphospholipid syndrome.

Coagulants are substances that promote the process of coagulation or clotting. They are often used in medical settings to help control bleeding and promote healing. Coagulants work by encouraging the formation of a clot, which helps to stop the flow of blood from a wound or cut.

There are several different types of coagulants that may be used in medical treatments. Some coagulants are naturally occurring substances, such as vitamin K, which is essential for the production of certain clotting factors in the body. Other coagulants may be synthetic or semi-synthetic compounds, such as recombinant activated factor VII (rFVIIa), which is used to treat bleeding disorders and prevent excessive bleeding during surgery.

Coagulants are often administered through injection or infusion, but they can also be applied topically to wounds or cuts. In some cases, coagulants may be used in combination with other treatments, such as compression or cauterization, to help control bleeding and promote healing.

It is important to note that while coagulants can be helpful in controlling bleeding and promoting healing, they can also increase the risk of blood clots and other complications. As a result, they should only be used under the guidance and supervision of a qualified healthcare professional.

Antithrombin III is a protein that inhibits the formation of blood clots (thrombi) in the body. It does this by inactivating several enzymes involved in coagulation, including thrombin and factor Xa. Antithrombin III is produced naturally by the liver and is also available as a medication for the prevention and treatment of thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. It works by binding to and neutralizing excess clotting factors in the bloodstream, thereby reducing the risk of clot formation.

Protein C is a vitamin K-dependent protease that functions as an important regulator of coagulation and inflammation. It is a plasma protein produced in the liver that, when activated, degrades clotting factors Va and VIIIa to limit thrombus formation and prevent excessive blood clotting. Protein C also has anti-inflammatory properties by inhibiting the release of pro-inflammatory cytokines and reducing endothelial cell activation. Inherited or acquired deficiencies in Protein C can lead to an increased risk of thrombosis, a condition characterized by abnormal blood clot formation within blood vessels.

Factor V, also known as proaccelerin or labile factor, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor V acts as a cofactor for the activation of Factor X to Factor Xa, which is a critical step in the coagulation cascade.

When blood vessels are damaged, the coagulation cascade is initiated to prevent excessive bleeding. During this process, Factor V is activated by thrombin, another protein involved in coagulation, and then forms a complex with activated Factor X and calcium ions on the surface of platelets or other cells. This complex converts prothrombin to thrombin, which then converts fibrinogen to fibrin to form a stable clot.

Deficiency or dysfunction of Factor V can lead to bleeding disorders such as hemophilia B or factor V deficiency, while mutations in the gene encoding Factor V can increase the risk of thrombosis, as seen in the Factor V Leiden mutation.

Factor IXa is a protein that plays a crucial role in the coagulation cascade, which is a series of biochemical reactions involved in blood clotting. It is an activated form of Factor IX, which is one of the coagulation factors that help convert prothrombin to thrombin, leading to the formation of a fibrin clot and stopping bleeding at the site of injury.

Factor IXa works by activating Factor X in the presence of calcium ions, phospholipids, and Factor VIIIa, which is another activated coagulation factor. This complex is called the tenase complex. The activation of Factor X leads to the formation of thrombin, which then converts fibrinogen to fibrin, forming a stable clot.

Deficiencies or dysfunctions in Factor IXa can lead to bleeding disorders such as hemophilia B, also known as Christmas disease, which is characterized by prolonged bleeding times and spontaneous bleeding episodes.

Blood tests, Coagulation system, Medical signs). ... of coagulation test which can be used to assess coagulation and ... A thrombin generation assay (TGA) or thrombin generation test (TGT) is a global coagulation assay (GCA) and type ... "Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications ... "Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?". Hamostaseologie. 40 (3): ...
All the diversity of clinical tests of the blood coagulation system can be divided into 2 groups: global (integral, general) ... tests, and «local» (specific) tests.[citation needed] Global tests, also known as global coagulation assays (GCAs), ... Blood clotting tests are the tests used for diagnostics of the hemostasis system. Coagulometer is the medical laboratory ... Local tests characterize the results of work of the separate components of the blood coagulation system cascade, as well as of ...
... blood coagulation tests and the battered child syndrome" (PDF). Singapore Medical Journal. 49 (6): 445-49. PMID 18581014. " ... Diseases: Coagulation, platelet and blood vessel diseases or deficiencies can increase bruising due to more bleeding. Location ... A broader definition of ecchymosis is the escape of blood into the tissues from ruptured blood vessels. The term also applies ... "Women with Red Hair Report a Slightly Increased Rate of Bruising but Have Normal Coagulation Tests". Anesthesia & Analgesia. ...
CS1: long volume value, Blood tests, Coagulation system, Medical signs). ... Whereas the aPTT-based APC resistance test only measures the initiation phase of coagulation, the ETP-based test is a global ... The activated protein C resistance (APCR) test is a coagulation test used in the evaluation and diagnosis of activated protein ... based test. The aPTT-based APC resistance test involves a modified aPTT test performed in the presence and absence of activated ...
... (TEG) is a method of testing the efficiency of blood coagulation. It is a test mainly used in surgery and ... More common tests of blood coagulation include prothrombin time (PT) and partial thromboplastin time (aPTT) which measure ... The signal of the pin suspended in the blood sample is transmitted via an optical detector system. The test is started by ... In this assay, a standard TEG is run twice - once using the patient's blood only and another time using the patient's blood ...
... is a method for blood coagulation monitoring and anticoagulant control. This test is based on imitation of ... Thrombodynamics takes into account the spatial heterogeneity trombodinamiki processes in blood coagulation. The test is ... of blood coagulation initiated by localized coagulation activator under conditions similar to the conditions of the blood ... 2006). "Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, ...
"Influence of the needle bore size on platelet count and routine coagulation testing". Blood Coagul Fibrinolysis. 17 (7): 557-61 ... butterflies based on belief that such small-bore needles hemolyze and/or clot blood samples and hence invalidate blood tests. ... When the needle enters the vein, venous blood pressure generally forces a small amount of blood into the set's transparent ... 25G butterflies connected directly to vacuum tubes caused the same amount of hemolysis and gave the same coagulation panel test ...
These are used to perform complete blood counts, erythrocyte sedimentation rates (ESRs), or coagulation tests. Automated cell ... Some tests and test categories are unique in their mechanism or scope, and require a separate analyser for only a few tests, or ... Depending on the test, different substances can be added to the blood plasma to trigger a clotting reaction. The progress of ... Automated coagulation machines or Coagulometers measure the ability of blood to clot by performing any of several types of ...
v t e (Blood tests, Coagulation system, Medical signs, All stub articles, Medical diagnostic stubs). ... Favaloro EJ, Lippi G (April 2019). "Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing". Semin Thromb ... which can be used as a coagulation test to assess thrombotic risk. It is the most widely used TGA. The CAT is a semi-automated ... "Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?". Hamostaseologie. 40 (3): ...
Blood clotting tests Disseminated intravascular coagulation Hepatic artery thrombosis Thrombotic microangiopathy Furie B, Furie ... and fibrin to form a blood clot to prevent blood loss. Even when a blood vessel is not injured, blood clots may form in the ... is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. When a ... The main mechanism is exposure of tissue factor to the blood coagulation system. Inflammatory and other stimuli (such as ...
... launched! - Diagnostica Stago v t e (Blood tests, Coagulation system, Medical signs, All stub articles, Medical ... Favaloro EJ, Lippi G (April 2019). "Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing". Semin Thromb ... and hence for coagulation testing. It was developed by Diagnostica Stago and was introduced by the company in 2018. ... "Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications ...
... and blood coagulation tests. The Oxfordshire Community Stroke Project classification (OCSP, also known as the Bamford or Oxford ... a disease of the blood vessels Arterial hypotension, or low blood pressure in the arteries Hypertension, or high blood pressure ... which can lead to deformed red blood cells clogging blood vessels and impeding blood flow Carotid artery stenosis, or narrowing ... Blood tests for risk factors also may be ordered, including cholesterol levels, triglyceride levels, homocysteine levels, ...
v t e v t e (CS1: long volume value, Blood tests, Coagulation system, All stub articles, Biochemistry stubs, Hematology stubs) ... F1+2 levels can be quantified with blood tests and is used in the diagnosis of hyper- and hypocoagulable states and in the ... Its biological half-life is 90 minutes and it persists in blood for a few hours after formation. The half-life of F1+2 is ... F1+2 is a marker of thrombin generation and hence of coagulation activation. It is considered the best marker of in vivo ...
Blood tests, Coagulation system, Medical signs). ... The test has also been used to study coagulation in feminizing ... The overall hemostatic potential (OHP) test is a global coagulation assay which can be used to measure coagulation. The OHP ... However, more studies are needed to validate the test as a biomarker of thrombosis and other abnormalities of coagulation. The ... Lim HY, Leemaqz SY, Torkamani N, Grossmann M, Zajac JD, Nandurkar H, Ho P, Cheung AS (July 2020). "Global Coagulation Assays in ...
The whole blood clotting test is a blood test used to check the coagulation mechanism in the blood following a snake bite. If ... The test is done by collecting 2 ml of venous blood in a dry and clean glass tube. The clot and stability of the formed clot is ... "Delayed double reading of whole blood clotting test (WBCT) results at 20 and 30 minutes enhances diagnosis and treatment of ... "Reliability of the simple 20 minute whole blood clotting test (WBCT20) as an indicator of low plasma fibrinogen concentration ...
"Epsilon aminocaproic acid reduces blood transfusion and improves the coagulation test after pediatric open-heart surgery: a ... control of oral bleeding in patients with congenital and acquired coagulation disorders, control of perioperative bleeding ...
It also often includes coagulation. Blood bank involves the testing of blood specimens in order to provide blood transfusion ... or blood bank determines blood groups, and performs compatibility testing on donor blood and recipients. It also prepares blood ... Other specialized tests include cell counts on various bodily fluids. Coagulation testing determines various blood clotting ... These tests, mostly automated, includes quantitative testing for a wide array of substances, such as lipids, blood sugar, ...
... is a blood test that characterizes coagulation of the blood. A historical name for this measure is the kaolin-cephalin clotting ... The blood is mixed, then centrifuged to separate blood cells from plasma (as partial thromboplastin time is most commonly ... measured using blood plasma). A sample of the plasma is extracted from the test tube and placed into a measuring test tube. ... Langdell RD, Wagner RH, Brinkhous KM (1953). "Effect of antihemophilic factor on one-stage clotting tests; a presumptive test ...
They developed a rapid and simple method for testing blood compatibility in which coagulation and the suitability of the blood ... A blood bank is a center where blood gathered as a result of blood donation is stored and preserved for later use in blood ... Several types of blood transfusion exist:[citation needed] Whole blood, which is blood transfused without separation. Red blood ... testing/treating, and transfusing their blood. Routine blood storage is 42 days or 6 weeks for stored packed red blood cells ( ...
... including complete blood count (CBC), urine toxicology, drug levels from blood, cultures, coagulation tests, assays for thyroid ... laboratory tests, imagery, and psychological testing to evaluate a person for physical and mental conditions. Once the person's ... A summary of more common and reported cases of factitious disorder (Munchausen syndrome), and the laboratory tests used to ... In some cases CT scan, magnetic resonance imaging, psychological testing, electroencephalography, or electrocardiography may ...
... analyzing blood transfusions for immune response, testing coagulation pathways, and organ transplantation viability. Their ... Gen-Probe was a company based in San Diego, in California, specializing in clinical diagnostics, blood screening, ... The company's molecular diagnostics products were used for diagnosis of infectious diseases, blood screening, ...
Blood, Hematology and Coagulation Testing Products, Blood Specimen Collection". www.fishersci.com. Retrieved 2022-12-16. ... are test tubes used in clinical chemistry tests requiring blood serum. SSTs are sometimes called "marble-top tubes", "tiger- ... After the blood sample is centrifuged, the clear serum should be removed for testing. These tubes should be used with care when ... Ilinskaya, Anna N; Dobrovolskaia, Marina A (June 2013). "Nanoparticles and the blood coagulation system. Part II: safety ...
Recommended laboratory blood testing includes: cross-matching blood, hemoglobin, hematocrit, platelets, coagulation time, and ... Although fecal occult blood testing has been used in an emergency setting, this use is not recommended as the test has only ... When there is significant blood loss over a short time, symptoms may include vomiting red blood, vomiting black blood, bloody ... Small amounts of bleeding may be detected by fecal occult blood test. Endoscopy of the lower and upper gastrointestinal tract ...
Doses ranging from 1 mg to 50 mg do not result in any changes in base line values in haematologic tests, routine blood ... chemistries, or coagulation parameters. Larger doses produce some side effects, but no electrocardiographic changes are ... Preclinical test conclude that the drug, in tested doses, appears to be safe for use in humans. Nisoxetine is a racemic ... Richard Kattau in the Rathbun laboratory tested the newly created drugs within the series of PPAs for their ability to reverse ...
... a coagulation blood test TT Electronics, a British maker of automotive components Tom Tailor, a German clothing company TT-Line ...
Blood tests, Coagulation system, Peptides). ... "Comparative aspects of blood coagulation". Vet J. 168 (3): 238- ... Hence, FpA levels provide a relatively transient measure of coagulation activation. Levels of FpA increase with age. FpA levels ... Douxfils J, Morimont L, Bouvy C (November 2020). "Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May ... Mannucci PM (October 1994). "Mechanisms, markers and management of coagulation activation". Br Med Bull. 50 (4): 851-70. doi: ...
... may refer to: Teenage Cancer Trust, a British charity organization Thrombin clotting time, a test used in blood coagulation ...
Two specific types of blood tests are used to aid in the diagnosis of Asherson's Syndrome. A coagulation blood test is used to ... An Enzyme-Linked ImmunoSorbent Assay (ELISA) test is done to detect anticardiolipin antibodies' presence in the blood. ... Positive test are often repeated due to the fact that antilipid antibodies can be present in the body for short stints due to ... The body contains β2-GPI, a glycoprotein in the blood, which is considered a natural anticoagulant due to its inhibitory ...
Doppler ultrasound Extremity arteriography Blood coagulation studies (Blood clotting tests) Prevention consists of walking, ... Frequent checks of the pulse, blood pressure, and temperature may be required. If the cause is not readily identifiable, tests ... Thrombophlebitis causes include disorders related to increased tendency for blood clotting and reduced speed of blood in the ... doi:10.1182/blood-2006-10-053736. ISSN 0006-4971. PMC 1976377. PMID 17496204. Tamparo, Carol D. (2016). Diseases of the Human ...
... assessment of uterus location and shape Laboratory tests - complete blood count, coagulation tests Vaginal bleeding may occur ... As the blood vessels in the cervix dilate, this leads to ruptures of membranes that allow blood and amniotic fluid to gather in ... Bloody show or show is the passage of a small amount of blood or blood-tinged mucus through the vagina near the end of ... Risk factors for preterm pregnancy such as high blood pressure, blood clotting issues, diabetes, sexually transmitted ...
... can be utilized in conjunction with blood glucose testing devices Shop NSP SAFETiCET™ ... and can be utilized in conjunction with blood glucose testing devices. ... A single use, sterile safety lancet for micro-blood sampling. This device aims to provide its user with minimal pain in its ... Protects healthcare personnel from needle stick accidents and direct contact with blood specimen ...
... producing high quality Vacuum Blood Collection EDTA Tube products. ... High quality 2ml Purple Top Vacuum Blood Collection EDTA Tube K3 Coagulation Tests from China, Chinas leading 2ml EDTA Tube ... Blood Collecting Tube Vacuum Blood Collection Tube Non Vacuum Blood Collection Tube Virus Sampling Tube Plain Blood Collection ... Whole blood: CBC, ESR, Coombs test, platelet antibodies, flow cytometry, blood levels of tacrolimus and cyclosporin. ...
These proteins help your blood to clot after injury. Learn more. ... test checks the function of certain proteins in your blood. ... Why do I need a coagulation factor test?. You may need this test if you have:. *An abnormal result on a blood test that checks ... What are Coagulation Factor Tests?. Coagulation factors are proteins in your blood. They help form blood clots to stop bleeding ... Coagulation factor tests are blood tests that check one or more of your clotting factors to see if you:. *Have too much or too ...
17 Hematology: Blood Coagulation Tests published on 01 Jan 2022 by ASHP. ...
... processing blood specimens; storing plasma for coagulation testing; and general recommendations for performing the tests. ... Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis ... This document provides procedures for collecting, transporting, and storing blood; ...
Perioperative point-of-care coagulation testing-recently published studies. [Article in German]. ... The International Foundation for Patient Blood Management Images Copyright: 123RF Stock Photo. Custom Websites for Non-Profit ...
Title: Effects of exercise stress testing on blood coagulation and fibrinolysis in aortic valve stenosis ... Effects of exercise stress testing on blood coagulation and fibrinolysis in aortic valve stenosis ... The role of blood coagulation in aortic stenosis and concomitant aneurysmatiuc dilation of ascending aorta ... To our knowledge, there have been no published studies on the effect of exercise on blood coagulation and fibrinolysis in AS ...
Blood tests, Coagulation system, Medical signs). ... of coagulation test which can be used to assess coagulation and ... A thrombin generation assay (TGA) or thrombin generation test (TGT) is a global coagulation assay (GCA) and type ... "Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications ... "Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?". Hamostaseologie. 40 (3): ...
Blood Coagulation Tests* * COVID-19 * Coronavirus Infections / blood* * Coronavirus Infections / physiopathology * Coronavirus ... Conventional coagulation assays, d-dimer levels, and viscoelastic measurements were analyzed using a receiver operating ... Derangements in coagulation laboratory values, including elevated d-dimer, fibrinogen, prothrombin time, and partial ... we hypothesized that deranged thromboelastography measurements of coagulation would correlate with thromboembolic events. ...
... and certain blood coagulation tests.. Materials and methods: Paired blood samples were obtained from each of 45 human ... Thus, we examined the effects of PTS on blood cell counts, erythrocyte sedimentation and several coagulation tests (PT and aPTT ... Upon reaching the laboratory, all blood samples were tested for coagulation analysis by centrifugation at 3500 × g for 10 ... The effects of transport by pneumatic tube system on blood cell count, erythrocyte sedimentation and coagulation tests. ...
Blood tests like hemoglobin levels, blood group • Liver and kidney function testsBlood coagulation test ( Prothromibin time ... What are the Tests Done Prior to Craniotomy? • Tests is required to diagnose the pathology • Helps to locate precisely within ... Clipping of an aneurysm • Clipping of aneurysm reduces blood flow through it and therefore decreases its size and its potential ... What are the risks? General complication 1. Bleeding 2. Infection 3. Blood clots 4. Reactions to anesthesia Specific ...
PakiMcqs.com is the Pakistani job test Mcqs website, where you can find Mcqs of all Subjects, You can also Submit Mcqs and your ... The presence if which of the following prevents coagulation of blood inside the human body:. Arslan Khalid ... The blood does not clot inside the body because of the presence of heparin in the blood. ... Arithmetic Mcqs , Basic Mathematics , Inspector Custom/Intelligence Officer job Test Mcqs If A completes a particular work in 4 ...
Blood Coagulation Testing Device 1 Kit Pack online in Pakistan and pay Cash on Delivery - Avail Flat 15% Discount on card ... Blood coagulation testing device, 1 kit pack. Key Benefits. -Coaguchek XS blood coagulation testing device requires a very ... Blood coagulation testing device, 1 kit pack. -For blood coagulation management. -Easy to use, requires very little amount of ... Coaguchek XS blood coagulation testing device is a convenient, portable, and user-friendly device for monitoring coagulation of ...
Blood Coagulation * Blood Coagulation Tests * Hemostasis * Hemostatics* * Humans * Liver Cirrhosis Substances * Hemostatics ... In vivo markers of activation of coagulation (thrombin-antithrombin III, D-dimer) were similarly elevated in both groups ...
... routine blood tests, coagulation function, and tumor markers; and (4) enhanced CT, MRI, or PET/CT examination. ... Apoptosis, Ki-67, cytokine, and killing assays were analyzed by a paired t-test. The p value of the difference in survival was ... As a control, CD8+ T cells and PBMCs from unrelated donors were used to test the allogeneic reaction of Vγ9Vδ2 T cells, and ... Human peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors using a Ficoll-Paque-based density gradient ...
CBC count, coagulation studies, liver function tests, peripheral blood smear. * Measurements of lipase, amylase, gamma globulin ... It is an easy, very sensitive, and specific test for visceral disease. In this case, the dipstick second from the left shows a ... Lemos EM, Carvalho SF, Corey R, Dietze R. [Evaluation of a rapid test using recombinant k39 antigen in the diagnosis of ... Other tests that may be considered include the following:. * ... Leishmanin (Montenegro) skin testing (LST) (not FDA approved in ...
Whole Blood Coagulation System Provides Multipurpose Point-of-Care Solution. Feb 3, 2004 , Coagulation Testing, Hematology & ... Roche to Expand Coagulation Testing Portfolio. Oct 4, 2011 , Coagulation Testing, Hematology & Serology, Miscellaneous ... Coagulation assays and test kits. Mar 19, 2003 , Coagulation Testing, Hematology & Serology, Miscellaneous ... Dade Behring Signs License and Research Agreement for New Coagulation Test. Jan 26, 2007 , Coagulation Testing, Hematology & ...
coagulation blood tests to see how quickly blood clots. *albumin tests to check for a protein produced in the liver ... Tests can reveal how damaged the liver has become. Some of the tests used for evaluation of cirrhosis are:. *a complete blood ... Liver function tests help determine the health of your liver. Learn about the most common liver function tests, why theyre ... If your blood is unable to pass through your liver, it creates a backup through other veins such as those in the esophagus. ...
Categories: Blood Coagulation Tests Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
Consult your doctor before taking this medicine if you have kidney problems, diabetes (high blood sugar levels), or any other ... A blood coagulation test is done to check the function of certain proteins in your blood. These proteins help your blood to ... Thyroid function tests are blood tests done to measure the functioning of your thyroid gland. Medronorm 10 mg Tablet is known ... Medronorm 10 mg Tablet should be used with caution as it may cause an alteration in blood sugar levels. Check your blood sugar ...
Blood test, clotting time. *Coagulation assessment blood test. Blood Brother Clinical Laboratories Also Affected by Price ... "low-volume tests, modified tests, manual interpretation tests, and humanitarian tests," she wrote. ... sought to change the current regulatory scheme for clinical laboratory-developed tests (LDTs) and in vitro clinical tests ( ... And even though existing tests would be largely exempted from oversight, "the utility of these tests would diminish over time ...
Abnormal results of coagulation blood tests or fetal heart rate monitoring support the diagnosis. ... Ultrasonography can show some cases of abruption; results of abnormal coagulation blood tests or fetal heart rate monitoring ... Kleihauer-Betke test if the patient has Rh-negative blood-to calculate the dose of Rho(D) immune globulin needed ... Complications of placental abruption (eg, shock, DIC) are managed with aggressive replacement of blood and blood products. ...
Results of blood tests including complete blood count, coagulation tests, liver enzymes, C-reactive protein, and cardiac ... and coagulation test results were all within reference ranges, and blood cultures were negative. Serology testing for ... PCR testing for C. burnetii (targeting insertion sequence 1111) in serum returned negative results. Repeated serologic testing ... Pacemaker testing 5 months and 12 months later showed no restoration of normal conduction. Repeated serologic testing showed no ...
Blood, Hematology and Coagulation Testing Products (1) * Blood Culture Systems and Supplies (1) ...
Coagulation tests on capillary blood (1 September, 1961) Katharine M. Dormandy, R. M. Hardisty ... The recognition of Hageman deficiency in blood donors (1 September, 1961) W. L. Marsh, W. J. Jenkins ... A contribution to the technique of intracutaneous testing with toxoplasmin (1 September, 1961) Otto Jírovec, Jindřich Jíra ... A SYMPOSIUM ON pH AND BLOOD GAS MEASUREMENT: METHODS AND INTERPRETATION ...
Blood test for coagulation assessment. $37 $50. Blood test for complete blood cell count (red cells, white cells, platelets), ... Blood test for testosterone level, total or assay. $29 $38. Blood test for the rate of sedimentation of red blood cells. $18 $6 ... Blood test for blood glucose control (hemoglobin A1C). $13 $13. Blood test for C-reactive protein (to detect infection or ... automated test (complete blood count). $47 $13. Blood test for complete blood cell count (red cells, white cells, platelets), ...
Initial laboratory investigations included complete blood count, coagulation function, and routine biochemical and liver ... The quantitative variables were compared by the Students t-test or the Mann-Whitney U test, when appropriate. Meanwhile, the ... Pearsons correlation test was used to determine the association between the two groups. The multivariate Cox proportional ... In the terms of laboratory findings, severe patients compared with the non-severe patients showed higher blood levels of ...
We have a special coagulation lab on-site to process blood clotting tests efficiently. ... When the blood doesnt clot, prolonged bleeding can occur.. At UW Health, we diagnose, treat and provide supportive care for ... Community Counts: Community Counts is a program of the CDCs Division of Blood Disorders. As part of this project, we gather ... Bleeding disorders refer to conditions in which blood doesnt clot as it should. Hemophilia is the most well-known of these ...
  • This is your basic hematology tube (by which I mean identifying and counting blood cells, blood typing, etc). (bloodcollectingtube.com)
  • K2EDTA is recommended by the CLSI (CLSI guideline - Evacuated Tubes and Additives for Blood Specimen Collection-Fifth Edition H1-A5, 2003) and the ICSH (International Council for Standardization in Hematology). (bloodcollectingtube.com)
  • Conventional coagulation assays, d-dimer levels, and viscoelastic measurements were analyzed using a receiver operating characteristic curve to predict thromboembolic outcomes and new-onset renal failure. (nih.gov)
  • Although monitoring is not required, effects on the various coagulation assays that are available are seen with its active form melagatran, and there are situations where an assessment of anticoagulant effect may help to inform clinical decisions. (mcmaster.ca)
  • However, the sensitivity of different coagulation assays varies considerably. (mcmaster.ca)
  • Comparing the various coagulation assays, the APTT, ECT, and TT are suitable choices when an indicator of the anticoagulant effect of ximelagatran is required, although the absence of international standards requires calibration of each test in individual laboratories and the ECT is not widely available. (mcmaster.ca)
  • Perioperative point-of-care coagulation testing-recently published studies. (patientbloodmanagement.org)
  • By Lisa Fratt The Hemochron Response whole blood coagulation system is a future-oriented system based on International Technidyne Corp's (ITC) decades of experience in point-of-care coagulation monitoring. (clpmag.com)
  • These tests include a prothrombin time test and INR (PT/INR) and/or a partial thromboplastin time test (PTT) . (medlineplus.gov)
  • Paired blood samples were obtained from each of 45 human volunteers and evaluated by blood cell count, erythrocyte sedimentation, and several coagulation tests, including prothrombin time (PT) and activated partial thromboplastin time (aPTT). (biochemia-medica.com)
  • To compare results obtained from plasma centrifuged for 5 minutes at 3000 g or for 10 minutes at 2000 g, 46 blood samples from normal healthy adults were assayed for prothrombin time, international normalized ratio and activated partial thromboplastin time. (who.int)
  • It is based on the potential of a plasma to generate thrombin over time, following activation of coagulation via addition of phospholipids, tissue factor, and calcium. (wikipedia.org)
  • In vivo markers of activation of coagulation (thrombin-antithrombin III, D-dimer) were similarly elevated in both groups compared to controls, but ex vivo thrombin-generating capacity was similar between patients and controls, despite a much more profound international normalized ratio elevation in ACLF. (nih.gov)
  • They help form blood clots to stop bleeding when you have an injury. (medlineplus.gov)
  • You have several different types of clotting factors that are all important for making blood clots. (medlineplus.gov)
  • But normally, clotting factors are turned off, so you don't form abnormal blood clots. (medlineplus.gov)
  • Your blood clots too easily, even without an injury. (medlineplus.gov)
  • This condition may lead to clots that block your blood flow and cause serious conditions, such as heart attack , stroke , or clots in the lungs . (medlineplus.gov)
  • Coagulation factor tests are also used to monitor people who have a known problem with clotting factors or who take medicine called blood thinners to lower the risk of blood clots. (medlineplus.gov)
  • They may also do a coagulation test to see how well your blood clots and how long it takes to do so. (healthline.com)
  • Your provider may order this test if you have repeated blood clots or if blood thinning medicine does not work. (medlineplus.gov)
  • Blood clots more easily, reducing the blood supply to the embryo. (or.jp)
  • These fibrin threads form a mesh to clump platelets because they are cross-linked to form blood clots. (medscape.com)
  • Fibrin and fibrinogen degradation product (FDP) testing is commonly used to diagnose disseminated intravascular coagulation (DIC). (medscape.com)
  • Fibrinogen degradation product (FDP) testing is commonly used to aid in the diagnosis of disseminated intravascular coagulation (DIC). (medscape.com)
  • False-positives results on fibrinogen degradation product (FDP) testing may be caused by rheumatoid factor. (medscape.com)
  • All patients underwent physical examination including assessment of growth and development, full blood count, blood electrolytes, liver function tests, and coagulation screen. (bmj.com)
  • The PTS yielded no observable effects on blood cell counts, erythrocyte sedimentation, or PT and aPTT test results. (biochemia-medica.com)
  • Dade Behring Inc has signed a license agreement with Radboud University Nijmegen Medical Centre (RUNMC), giving Dade Behring the exclusive rights for a new coagulation test called the Nijmegen Hemostasis Assay (NHA). (clpmag.com)
  • A thrombin generation assay (TGA) or thrombin generation test (TGT) is a global coagulation assay (GCA) and type of coagulation test which can be used to assess coagulation and thrombotic risk. (wikipedia.org)
  • This device only requires 8 microliters of capillary blood. (dawaai.pk)
  • The researchers measured cycle threshold (CT) values from the SARS-CoV-2 real-time PCR and serological results, which included blood test, biochemical analysis, C-reactive protein (CRP), interleukin-6 (IL-6), SARS-CoV-2 IgG antibody titer , blood coagulation function, and microbe testing. (news-medical.net)
  • Viral tests (nucleic acid or antigen detection tests) are used to assess acute infection, whereas antibody tests provide evidence of prior infection with SARS-CoV-2. (medscape.com)
  • The US Food and Drug Administration [FDA] has not authorized the use of antibody tests for the diagnosis of acute infection. (medscape.com)
  • Serum tests for both IgG and IgM antibody to toxoplasmosis will be added to the NHANES 2001 laboratory protocol to obtain the most accurate information available about the prevalence of toxoplasmosis in the U.S. and determine if the rates are changing over time. (cdc.gov)
  • Bleeding disorders can lead to serious blood loss after an injury. (medlineplus.gov)
  • Bleeding disorders refer to conditions in which blood doesn't clot as it should. (uwhealth.org)
  • Community Counts is a program of the CDC's Division of Blood Disorders. (uwhealth.org)
  • The clinical development of ximelagatran for the treatment and prevention of various arterial and venous thromboembolic disorders has used fixed-dose regimens without coagulation monitoring in all indications. (mcmaster.ca)
  • Laboratory testing for functional platelet disorders is appropriate in individuals with bleeding manifestations that suggest a functional platelet disorder (eg, easy bruising, prolonged bleeding following dental work or surgery, menorrhagia), particularly those with a family history of a bleeding disorder and in whom VWD has been previously excluded. (arupconsult.com)
  • These tests can help rule out other possible causes of the amnesia (eg, severe anemia, clotting disorders). (msdmanuals.com)
  • An abnormal result on a blood test that checks how long it takes your blood to clot. (medlineplus.gov)
  • Disseminated Intravascular Coagulation (DIC) Disseminated intravascular coagulation (DIC) involves abnormal, excessive generation of thrombin and fibrin in the circulating blood. (merckmanuals.com)
  • Abnormal test results may be indicative of inflammation or cancer. (medicalhealthtests.com)
  • aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of abnormal platelet function, and platelet function testing may need to be deferred if patients have been taking these medications. (arupconsult.com)
  • Diagnostic testing occurs when physicians require more information for evaluation and/or diagnosis of a patient. (colletonmedical.com)
  • EDTA prevents clotting by chelating calcium, an essential component of coagulation. (bloodcollectingtube.com)
  • The platelets release molecules into your blood that begin to turn on the clotting factors. (medlineplus.gov)
  • The clotting factors work together in a chain reaction to form a harder blood clot that will stay firmly in place. (medlineplus.gov)
  • A coagulation factor test is used to find out if you have a problem with any of your clotting factors that may cause too little or too much blood clotting. (medlineplus.gov)
  • Is it true that clotting of blood is same as coagulation of blood? (healthtap.com)
  • Clotting = coagulation. (healthtap.com)
  • If your blood is clotting too much, do you need to get surgery? (healthtap.com)
  • I'm having symptoms of blood clotting. (healthtap.com)
  • What can I do if I have an unstable acute angina and my blood is not clotting? (healthtap.com)
  • I know they're basically all important but what would you say is the most important clotting factor to have in the blood? (healthtap.com)
  • How are blood coagulation and blood clotting different? (healthtap.com)
  • What can cause excessive clotting of the blood? (healthtap.com)
  • How is blood clotting bad? (healthtap.com)
  • What causes blood clotting? (healthtap.com)
  • What effects the clotting ability of blood? (healthtap.com)
  • After a blood vessel is injured, platelets in the blood come to help the clotting process. (healthline.com)
  • Clotting prevents the injured blood vessels from leaking any more blood and making your bruise even bigger. (healthline.com)
  • Some proteins in your blood, called clotting factors, also help to stop the bleeding so that the tissue starts healing. (healthline.com)
  • Antithrombin III (AT III) is a protein that helps control blood clotting. (medlineplus.gov)
  • Lower-than-normal AT III may mean you have an increased risk for blood clotting. (medlineplus.gov)
  • When you have an injury that causes bleeding, blood cells called platelets begin to make a soft blood clot to stop the bleeding. (medlineplus.gov)
  • Your blood doesn't clot enough after an injury or surgery. (medlineplus.gov)
  • The blood does not clot inside the body because of the presence of heparin in the blood. (pakimcqs.com)
  • Medronorm 10 mg Tablet is not recommended for use if you have or recently have had a stroke (brain damage due to interrupted blood supply to the brain), heart attack, or blood clot disorder, as it may worsen your condition. (practo.com)
  • When the blood doesn't clot, prolonged bleeding can occur. (uwhealth.org)
  • A blood clot is caused by an injury to an artery or vein that activates the coagulation cascade. (medscape.com)
  • This device aims to provide its user with minimal pain in its piercing operation, and can be utilized in conjunction with blood glucose testing devices. (fishersci.com)
  • Plasma stored from EDTA-treated blood can also be used to measure most proteins, and genetic material can easily be stored from EDTA buffy coats (the interface between the red cells and the plasma after centrifugation, containing white cells and platelets). (bloodcollectingtube.com)
  • Coagulation factors are proteins in your blood. (medlineplus.gov)
  • An initial step in detecting liver damage is a simple blood test to determine the level of certain liver enzymes (proteins) in the blood. (medicinenet.com)
  • we hypothesized that deranged thromboelastography measurements of coagulation would correlate with thromboembolic events. (nih.gov)
  • Repeated serologic testing showed no evidence for progression to chronic disease, and repeated echocardiography and FDG/PET-CT showed no focal infection. (cdc.gov)
  • With any type of laboratory test, the clinical accuracy or reliability depends on performance characteristics such as sensitivity and specificity, as well as the pretest probability that a person has SARS-CoV-2 infection and the prevalence of COVID-19 in the local community. (medscape.com)
  • On the basis of historical information, as well as serologic testing, sporadic Lassa infection may have occurred also in Guinea, Senegal, Mali, and the Central African Republic (6,7). (cdc.gov)
  • Molecular Testing of SARS-CoV-2 Infection from Blood Samples in Disseminated Intravascular Coagulation (DIC) and Elevated D-Dimer Levels. (cdc.gov)
  • Blood and urine specimens are collected on participants aged one year and older at the mobile examination centers (MECs). (cdc.gov)
  • The laboratory component of NHANES includes the collection, processing, storage, and shipping of blood, urine and other biological and environmental specimens. (cdc.gov)
  • The blood collection procedure consists of administering a questionnaire to screen for conditions that excludes the participants from the blood draw and determines fasting status, a blood draw, and collecting specimens for special studies. (cdc.gov)
  • The Coulter MAXM performs a complete blood count on blood specimens to provide a study of blood cells and coagulation for all participants. (cdc.gov)
  • The aim of this study was to examine the influence of PTS on the quality of routine blood cell counts, erythrocyte sedimentation, and certain blood coagulation tests. (biochemia-medica.com)
  • We concluded that the PTS can be used to transport blood samples and yield reliable results for blood cell counts, erythrocyte sedimentation, and several coagulation tests. (biochemia-medica.com)
  • Heparin acts at multiple sites in the normal coagulation system. (nih.gov)
  • In order to facilitate pre-cruise testing requirements, Norwegian has partnered with Inspired Diagnostics lab to ensure that guests have access to a quick, efficient and easy way to access the required FDA-approved proctored in-home antigen test prior to embarkation from the comfort of their own home. (ncl.com)
  • This can be used to assess APC resistance and is termed the ETP-based APC resistance test. (wikipedia.org)
  • Physicians and other clinical staff usually assess the quality of laboratory service by the period of elapsed time between analysis and test results, and they often assume faster is better. (biochemia-medica.com)
  • These tests can be used to assess liver functions or liver injury. (medicinenet.com)
  • OBJECTIVE: To explore the laboratory phenotype and molecular pathogenesis in a Chinese pedigree affected with Hereditary coagulation factor â « (Fâ «) deficiency. (bvsalud.org)
  • BACKGROUND AND AIMS: We aimed to elucidate a hereditary mutation of coagulation factor XII (FXII) in a consanguineous Chinese family. (bvsalud.org)
  • The blood sample test results from groups 1 and 2 were evaluated and compared. (biochemia-medica.com)
  • TAT is defined as the period of time for blood draw, sample delivery, analysis, and results. (biochemia-medica.com)
  • Coaguchek XS blood coagulation testing device gives precise and accurate PT/INR results within one minute. (dawaai.pk)
  • Liver enzyme, cardiac troponin, and coagulation test results were all within reference ranges, and blood cultures were negative. (cdc.gov)
  • PCR testing for C. burnetii (targeting insertion sequence 1111) in serum returned negative results. (cdc.gov)
  • Results of blood tests done during his hospitalization to determine coagulation parameters were consistently normal. (cdc.gov)
  • Certain medicines may affect the results of the test. (medlineplus.gov)
  • Talk to your provider about the meaning of your specific test results. (medlineplus.gov)
  • Preanalytical and biological variability both have strong influences on test results of coagulation. (edu.au)
  • Although it is impractical to develop reference ranges specific to the daily concentration of air pollutants, the potential influence of air pollution on results of coagulation testing should be recognised when interpreting laboratory findings. (edu.au)
  • As many as 50% of positive blood culture results have been estimated to be falsely positive. (medscape.com)
  • This rate probably has decreased, but false-positive blood culture results remain a major diagnostic challenge. (medscape.com)
  • We would like to remind clinicians to please refer patients to state and local health departments for COVID-19 testing and test results. (cdc.gov)
  • Clinicians should not refer patients to CDC to find out where or how to get tested for COVID-19 or obtain test results. (cdc.gov)
  • For laboratory tests with a lower detection limit, results below the lower detection limit are replaced with a value equal to the detection limit divided by the square root of two. (cdc.gov)
  • No significant differences were found in test results and it was concluded that 5 minutes centrifugation at 3000 g is a reliable and useful option to reduce the turnaround time for these tests. (who.int)
  • The results of a rapid latex agglutination test kit parallel the results of the hemagglutination inhibition (HAI) method in detecting levels of 10 mcg/mL or higher. (medscape.com)
  • the VALID Act contains many provisions that are similar to policy the CAP has advocated for regarding the regulation of laboratory tests since 2009. (darkdaily.com)
  • Examples of laboratory tests include biopsies, blood tests and urine samples. (colletonmedical.com)
  • The cost of a breast augmentation surgery includes consultation by a plastic and reconstructive surgery physician, breast echoscopy and laboratory tests required before surgery, surgery and any additional postoperative measures (such as a special corset), catering (from day 2). (medcentras.lt)
  • Laboratory tests should include complete blood count (CBC), coagulation tests, and evaluation for hypercoagulable states. (msdmanuals.com)
  • Hematological profiles are complete for all participants, and specified laboratory tests are performed upon each specimen based on the participant's age at time of interview and sex. (cdc.gov)
  • Two sets of blood cultures have greater than 90% sensitivity when bacteremia is present. (medscape.com)
  • If both NP and OP swabs are collected, they can be combined in a single tube to maximize test sensitivity and conserve transport devices. (medscape.com)
  • In angina bullosa hemorrhagica (ABH), platelet counts and coagulation tests are within normal limits. (medscape.com)
  • Currently, there are three basic types of tests to determine if an individual has been infected with SARS-CoV-2: viral nucleic acid (RNA) detection, viral antigen detection, and detection of antibodies to the virus. (medscape.com)
  • eMed or BioReference-Scarlett Concierge testing service - BioReference sends a trained Scarlet Health Professional to your home to collect your COVID-19 test specimen. (ncl.com)
  • Collecting the appropriate specimen at the right time and transporting it to the laboratory under proper conditions are critical pre-analytic components of the testing process. (medscape.com)
  • if it is negative for SARS-CoV-2, an LRT specimen can be collected and tested. (medscape.com)
  • further testing may include platelet aggregation tests, platelet flow cytometry, and in some cases, genetic testing. (arupconsult.com)
  • On March 6, a routine blood chemistry screen showed elevations of total bilirubin, alkaline phosphatase, gamma glutamyl-transferase, serum glutamic oxalacetic transaminase, and lactate dehydrogenase. (cdc.gov)
  • Blood samples were divided into 2 groups: Samples from group 1 were transported to the laboratory via the PTS, and samples from group 2 were transported to the laboratory manually. (biochemia-medica.com)
  • Although PTS significantly reduces the laboratory TAT, the samples do withstand forces of pressure during transport, such as changes in air pressure, movement or shaking of blood in the test tube, vibrations, and sudden accelerations and decelerations These pressures can potentially affect laboratory measurements during tests, such as blood gas analysis, routine haematology and coagulation tests, and spectrophotometric analysis of the cerebrospinal fluid. (biochemia-medica.com)
  • PPPatroomtemperaturewithin1hof coagulationtherapy[ 1 ].Qualitycare Between25Februaryand28May2006, col ectionbycentrifugingthesecond requiresreliabletestresultsandprompt blood samples were taken from 46 drawtubesat3000gfor5minandthe turnaroundtimes.Reliableresultscan healthyvolunteersattheUniversityof thirddrawtubesat2000gfor10min. (who.int)
  • The normal range of values for AST (SGOT) is about 5 to 40 units per liter of serum (the liquid part of the blood). (medicinenet.com)
  • Repeated serologic testing 4 weeks later demonstrated titers of phase II IgG had increased to 3,200. (cdc.gov)
  • Serologic tests are available to determine who has become infected with toxoplasmosis. (cdc.gov)
  • Pacemaker testing 5 months and 12 months later showed no restoration of normal conduction. (cdc.gov)
  • What blood tests would I need to determine if my blood coagulation is normal? (healthtap.com)
  • A health care professional will take a blood sample from a vein in your arm, using a small needle. (medlineplus.gov)
  • Dade Behring Inc has announced that it has introduced the capability to connect the Sysmex® CA-7000 Coagulation Analyzer to the StreamLAB® Analytical Workcell, one of the company's customized automation solutions for the clinical laboratory. (clpmag.com)
  • In 2022, a bill before Congress titled the Verifying Accurate Leading-Edge IVCT Development Act (VALID Act) sought to change the current regulatory scheme for clinical laboratory-developed tests (LDTs) and in vitro clinical tests (IVCTs). (darkdaily.com)
  • This impact may cause a blood vessel to burst open leaking blood under the skin, creating a bruise. (healthline.com)
  • In some cases following a paracentesis, complications may arise such as puncture of a blood vessel, bladder or bowel. (medicalhealthtests.com)
  • γδ T cells, specifically the Vγ9Vδ2 subset, which is the dominate subset among γδ T cells in human peripheral blood, recognize target cells in a human leukocyte antigen (HLA)-independent manner. (nature.com)
  • It also allows you to search by test type - PCR or Antigen. (ncl.com)
  • The workup of a patient with a platelet-type bleeding pattern typically includes correlation with platelet count ( thrombocytopenia ), evaluation of platelet morphology on peripheral smear, exclusion of acquired causes of platelet dysfunction, and testing for von Willebrand disease (VWD) . (arupconsult.com)
  • Initial laboratory testing for a functional platelet disorder includes a CBC with platelet count and a peripheral smear. (arupconsult.com)
  • It is used to diagnose disseminated intravascular coagulation. (medscape.com)
  • While acknowledging that it had room for improvement, she lauded the bill's three-tier risk-based system, in which tests deemed to have the greatest risks would receive the highest level of scrutiny. (darkdaily.com)
  • Because the signs and symptoms of coronavirus disease 2019 (COVID-19) may overlap with those of other respiratory pathogens, it is important to perform laboratory testing to specifically identify symptomatic individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). (medscape.com)
  • In the laboratory the blood is processed, stored and shipped to the Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention for analysis. (cdc.gov)
  • Serology testing for brucellosis was negative. (cdc.gov)
  • Serology testing for C. burnetii demonstrated positive phase II IgM, phase II IgG with a titer of 1:100, and negative phase I IgG. (cdc.gov)
  • The ETP-based APC resistance test was developed in 1997. (wikipedia.org)
  • Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. (medscape.com)
  • You may have tests for one or more factors at a time. (medlineplus.gov)
  • The researchers also assessed the nucleic acid negativization (NAN), which is defined as 'the duration from the first day of the positive nucleic acid report to the time of the second negative nasopharyngeal swab testing of the two successive negative nucleic acid tests. (news-medical.net)
  • Garlick JA, Calderon S. Oral blood blisters in angina bullosa haemorrhagica secondary to trauma of eating and dental injection. (medscape.com)
  • During the first few days, your doctor will monitor your blood thinning level and may determine your need for additional blood transfusions. (umms.org)
  • A blood test can determine the amount of AT III present in your body. (medlineplus.gov)
  • Test to determine the ratio of Th1 and Th2 cells. (or.jp)